Gilead Sciences, Inc. GILD
150.93
1.24
0.83%
as of 25 Sep
- Market cap
- $183.2B
- P/E
- 0.0×
Follow GILD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Gilead Sciences, Inc. (GILD) Gross margin
Gilead Sciences, Inc.'s gross margin over the twelve months to 30 June 2026 was 79.6%, up 0.8 percentage points from fiscal 2025 (78.8%). Over the past ten years it has ranged from 75.8% (fiscal 2021) to 87.7% (fiscal 2015); the current reading is higher than 45% of that period. That is above the Drug Manufacturers General industry median of 72.8% and above the Healthcare sector median of 53.7%.
Gross margin, annual
Annual
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 78.8% | 0.57 |
| FY2024 | 78.3% | 2.22 |
| FY2023 | 76.0% | (3.22) |
| FY2022 | 79.3% | 3.44 |
| FY2021 | 75.8% | (5.66) |
| FY2020 | 81.5% | 2.30 |
| FY2019 | 79.2% | 1.11 |
| FY2018 | 78.1% | (5.19) |
| FY2017 | 83.3% | (2.72) |
| FY2016 | 86.0% | (1.75) |
Quarterly
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 79.8% | 0.52 |
| Mar 2026 | 79.2% | (0.27) |
| Dec 2025 | 79.5% | (0.29) |
| Sep 2025 | 79.8% | 0.99 |
| 42 more quarters | Free account |
Against its own ten years
Low 75.8%
High 87.7%
Ten-year median
79.2%
Current reading's percentile
45
Gross margin against peers
| Company | Gross margin |
|---|---|
| AZN AstraZeneca PLC compare | 81.9% |
| NVO Novo Nordisk A/S compare | 80.7% |
| GILD Gilead Sciences, Inc. | 79.6% |
| NVS Novartis AG compare | 74.7% |
| PFE Pfizer Inc. compare | 73.2% |
| SNY Sanofi compare | 72.8% |
| GSK GSK PLC Sponsored ADR compare | 72.8% |
| BMY Bristol Myers Squibb Company compare | 70.2% |
| AMGN Amgen Inc. compare | 69.5% |
| Drug Manufacturers General industry median | 72.8% |
| Healthcare sector median | 53.7% |
| Market median | 46.3% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on GILD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement